Abstract
To investigate the phracokinetics of isosorbide-5-mononitrate (ISMN) in hemodialysis patients, 20mg of ISMN was administered twice a day to six chronic hemodialysis patients with ischemic heart disease. Beginning more than three days after the administration, blood samples were taken periodically to determine the ISMN blood concentration. The blood concentration of ISMN on non-hemodialysis day was extremely high, and a decrease in the distribution volume was suggested to be the main cause. The elimination rate of ISMN was almost 80% during hemodialysis, however the blood concentration of ISMN remained within the therapeutic range after hemodialysis.
It was concluded that no dose adjustment appeared necessary in hemodialysis patients, although the blood concentration of ISMN was influenced by hemodialysis.
